Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) revealed on Monday that it has joined the CAN Health Network, a federally funded initiative aimed at accelerating the integration of Canadian technologies into the national healthcare system.

Membership grants Ondine access to strategic partnerships, market insights and commercial pathways to scale its Steriwave nasal photodisinfection technology across Canada. Steriwave, a proprietary light-activated antimicrobial, targets infection prevention without contributing to antimicrobial resistance.

Clinical data supports Steriwave's impact, including a 66.5% reduction in spine surgery infections at Vancouver General Hospital and a 70% reduction in joint replacement infections at Mid Yorkshire NHS Teaching Trust. A separate study by the York Health Economics Consortium estimated potential NHS cost savings of up to GBP200m annually.

Approved in multiple international markets, Steriwave holds CE mark status in Europe and regulatory clearance in Canada, Australia and Mexico. In the US, it has been granted FDA Fast Track and Qualified Infectious Disease Product designations and is currently in clinical trials.

Ondine continues to develop its photodisinfection pipeline across indications such as sinusitis, ventilator-associated pneumonia, and burn-related infections.